Results 51 to 60 of about 184,433 (313)

Phase 1 study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

, 2004
We assessed the safety, tolerability and efficacy of the immunomodulatory drug, CC-5013 (REVIMID(TM)), in the treatment of patients with metastatic malignant melanoma and other advanced cancers.
Muller, G.W., Dredge, K., Clarke, IA, Kristeleit, H., Dredge, K, D I Stirling, A G Dalgleish, Zeldis, J., S Nicholson, Polychronis, A., Kristeleit, H, G W Muller, H Kristeleit, J B Bartlett, Nicholson, S, K Dredge, Stirling, D.I., Michael, A, Dalgleish, A.G., Polychronis, A, Muller, GW, Pandha, H,, Stirling, DI, I A Clarke, Clarke, I.A., Bartlett, JB, Zeldis, J, Nicholson, S., H Pandha, Dalgleish, AG, J Zeldis, Pandha, H, A Polychronis, Michael, A., A Michael, Bartlett, J.B.   +35 more
core   +1 more source

Advances in immunotherapy for melanoma management [PDF]

Human Vaccines & Immunotherapeutics, 2016
Melanoma remains a leading cause of death among young adults. Evidence that melanoma tumor cells are highly immunogenic and a better understanding of T-cell immune checkpoints have changed the therapeutic approach to advanced melanoma. Instead of targeting the tumor directly, immunotherapy targets and activates the immune response using checkpoint ...
Mohammed, Dany, Rose, Nganga, Alissar, Chidiac, Edith, Hanna, Sara, Matar, Dirk, Elston   +5 more
openaire   +2 more sources

The price of tumor control [PDF]

, 2013
Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients.
Berking, Carola, Bockmeyer, Clemens L., Voskens, Caroline J., Fluck, Michael, Heinzerling, Lucie M., Schuler, Gerold, Vaubel, Julia, Keller, Ullrich, Goldinger, Simone M., Wilhelm, Tabea, Moos, Roger von, Mohr, Peter, Eigentler, Thomas, Paetzold, Sylvie, Justich, Armin, Hundorfean, Gheorghe, Hauschild, Axel, Mateus, Christine, Klein, Christina, Loquai, Carmen, Schadendorf, Dirk, Göppner, Daniela, Robert, Caroline, Bergmann, Tanja, Gutzmer, Ralf, Hein, Rüdiger, Grabbe, Stephan, Dummer, Reinhard, Kaehler, Katharina C., Trefzer, Uwe, Ulrich, Jens, Weder, Patrik, Schuler-Thurner, Beatrice, Garbe, Claus, Satzger, Imke, Schlaeppi, Marc   +35 more
core   +1 more source

Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER–Medicare database

Therapeutic Advances in Drug Safety, 2021
Background: The use of anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) therapy (ipilimumab) and anti-programmed cell-death 1 (anti-PD1) agents (nivolumab and pembrolizumab) in advanced melanoma have been associated with immune-related adverse events ...
Abdulaali R. Almutairi, Marion Slack, Brian L. Erstad, Ali McBride, Ivo Abraham   +4 more
doaj   +1 more source

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

Molecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh, Nitzan Medina‐Itzhaki, Milena Chekov, Eden Gal‐Swisa, Roba Gabesh‐Wahabi, Inbar Savyon, Inna Naroditsky, Hilary A. Kenny, Basem Fares, Lina Korsensky, Einav Girsh, Liron Berger, Ruth Perets   +12 more
wiley   +1 more source

Epigenetic Regulation in Melanoma: Facts and Hopes

Cells, 2021
Cutaneous melanoma is a lethal disease, even when diagnosed in advanced stages. Although recent progress in biology and treatment has dramatically improved survival rates, new therapeutic approaches are still needed.
Emilio Francesco Giunta, Gianluca Arrichiello, Marcello Curvietto, Annalisa Pappalardo, Davide Bosso, Mario Rosanova, Anna Diana, Pasqualina Giordano, Angelica Petrillo, Piera Federico, Teresa Fabozzi, Sara Parola, Vittorio Riccio, Brigitta Mucci, Vito Vanella, Lucia Festino, Bruno Daniele, Paolo Antonio Ascierto, Margaret Ottaviano, On Behalf of SCITO YOUTH   +19 more
doaj   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Penile melanoma

, 2021
Penile melanoma is a rare event, responsible for less than 1.4% of penile cancers. In general, it is late diagnosed and the treatment is usually aggressive.
Marcus Maia, Fernanda Monteiro Orellana, Roni de Carvalho Fernandes, Luis Gustavo Morato de Toledo, João Pedro Vaz de Souza Cabral Simões, Rute Facchini Lellis, Luiz Felipe de Mello Pereira Leitão   +6 more
core   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Prospects for non-immunological molecular therapeutics in melanoma [PDF]

, 2010
In 2006 there were 60,000 new cases of cutaneous melanoma in the European Union and 13,000 deaths (www.europeancancerleagues.org). Currently available systemic treatment options for metastatic melanoma, including both cytotoxic and immunologic therapies,
Tryfonopoulos, Dimitrios, Eustace, Alexander J., Mahgoub, Thamir, O\u27Donovan, Norma, Crown, John, O'Donovan, Norma   +5 more
core